Trial Profile
Clinical Study on the Safety and Efficacy of Anti-Mesothelin Car NK Cells With Epithelial Ovarian Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 11 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-mesothelin-CAR-NK-cell-therapy-Allife-Medical-Science-and-Technology (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors Allife Medical Science and Technology
- 30 Jan 2019 Planned initiation date changed from 1 Nov 2018 to 1 Mar 2019.
- 10 Oct 2018 New trial record